Immunological
Rocatinlimab has met primary endpoints in Phase III studies, but analysts question the Kyowa-discovered drug’s market potential due to tolerability and unspectacular efficacy.
Deal Snapshot: Following alliances with BMS, Genentech and Pfizer, Repertoire is partnering with Lilly to discover T-cell targeted autoimmune therapies. Deal continues a busy January for Lilly’s business development.
Paul Hudson has acknowledged the firm’s R&D setbacks but says they are par for the course when tackling science ‘that has never been done before.’
The Belgian biotech is closing its CAR-T division and pivoting to a new de-risked business development model, with the blessing of long-term investor, Gilead.
Deal Snapshot: The German group is the latest big pharma to partner with one of China's most prolific dealmakers in an agreement that could be worth over $1bn.
Fund IV exclusively targets company creation and early-stage investing across the UK and the US.
The Paris-headquartered giant has heralded data from two new Phase III trials of the anti-OX40L antibody but there are still concerns over its level of efficacy.
The US biotech has upsized its public offering to $175m after the success of soquelitinib in a very early trial for atopic dermatitis.
HUTCHMED sees good potential for its Syk inhibitor in autoimmune setting following positive topline Phase III results, with China NDA planned in first half.
Just a week after the J.P. Morgan Healthcare conference, GSK’s first buyout of 2026 is focused on anti‑IgE antibody, ozureprubart, which is in Phase II development for prophylactic protection against food allergens.
CEO Jean-Christophe Tellier tells attendees at the San Francisco meeting that there is much more to come from Bimzelx.
With more than $112m in new funding, the company plans further development of its Phase I IL23p19xTL1A-directed bispecific candidate.
Upcoming product launches from partnerships with J&J and Takeda could generate billions in royalties for the biotech, which now aims to build an in-house portfolio of next-generation oral obesity drugs and I&I therapies.
Another Phase III hit for Lilly’s Zepbound, the TOGETHER-PsA trial is the first to add an incretin therapy to anti-inflammatory biologic, potentially expanding its reach into another major comorbidity market.
The Swiss biotech’s shares jumped by 27% after the US agency said another trial was not needed to submit sonelokimab.
The company plans to move cizutamig, its T-cell engager targeting BCMA, into Phase II studies in 2026, while planning to generate additional data from its CD20-directed asset.
The acquisition signals growing belief in the NLRP3 inhibitor class, where companies are increasingly pursuing cardiometabolic and obesity studies alongside neurodegenerative trials.
The company announced positive Phase III data testing envudeucitinib in psoriasis and plans to file an NDA in late 2026.
CEO and co-founder Tim Van Hauwermeiren will transition to chairman of the board of directors.
Atopic dermatitis is an indication that continues to elude the immunology power player.